Male Grooming
components are involved, including miRNAs, recently linked to the hair cycle. Currently, two chemical molecules have been
Hairgenyl provides an original and natural approach, reactivating the dermal papilla and stimulating hair follicle growth.
commercialised to treat androgenetic alopecia. the cases and their side effects are considerable,
A double hair regrowth and anti-hair loss efficacy
being oily hair, the appearance of dandruff, skin
An initial in vivo study was carried out with the
irritations, and libido issues. So, there is a genuine
phototrichogram to determine the hair regrowth
need to find a new approach that favours hair
effect of Hairgenyl formulated at 0.3 percent
growth while preventing the above-mentioned
in a lotion (see Figure 2). This experiment was
side effects 5.
conducted on a panel of 22 male volunteers with
Unfortunately, they are effective in less than half
There is a genuine need to find a new approach that favours hair growth
slight to moderate alopecia (mean
Development of 2D and 3D models
age of 43 ± eight years), applying the
To identify and demonstrate the efficacy of
product twice a day for eight months.
Hairgenyl, Silab developed 2D and 3D cell
The following parameters were analysed:
and tissue models mimicking androgenetic
hair density; number of hairs in anagen
alopecia. The 2D model of fibroblasts from the
phase (indicator of hair growth);
dermal papilla was adopted to define Hairgenyl’s
anagen/telogen ratio (hair growth
mechanism of action. The 3D tissue model of
coefficient); and the number of hairs in
spheroids mimicking the architecture of the
telogen phase (indicator of resting hair).
papilla and ex vivo studies on hair follicles (see
The capacity of Hairgenyl to
Figure 1) was used to determine the effect of the
reactivate hair growth is proven after
active ingredient on the function of the dermal
eight months of treatment; hair density increased
papilla. The biological modifications occurring
by +24.9 percent (P = 0.0001). The number of hairs
during androgenetic alopecia were mimicked by
in anagen phase increased by +49.1 percent
treating certain models with dihydrotestosterone
(P = 0.0001), whereas the number of hairs in
– a hormone classically used to induce
the telogen phase decreased by -26.1 percent
these disorders.
(P = 0.0001). This resulted in an increase of the
Demonstrated in 2D and 3D models, Hairgenyl acts on the three main (aforementioned) regulation mechanisms of hair regrowth. Silab
A/T ratio of +112.7 percent (P = 0.0005). A second in vivo
has proven for the first time that increasing
study was conducted to
mitochondrial fusion boosts the capacity for
determine the capacity
energy production, which is consumed in hair
of Hairgenyl, formulated
follicle growth. Tested at 0.04 percent on human
at 0.3 percent in a lotion,
hair follicle dermal papilla cells, Hairgenyl
to reduce hair loss in
stimulates the synthesis of mitofusin 1, which is
volunteers with slight
a protein involved in mitochondrial fusion, by
to moderate alopecia.
+52 percent.
This wash test carried
When tested on human hair follicle dermal
out by a professional
papilla cells treated with DHT, Hairgenyl at
hairdresser included
0.04 percent limits the expression of three
22 male volunteers (mean
signalling molecules in the microenvironment of
age of 43 ± eight years),
the dermal papilla, essential for hair growth:
who applied the product
1. IL-6 (interleukin-6) by -97 percent, which inhibits
twice a day for eight
growth of the hair shaft 2. DKK1 (Dickkopf 1) by -91 percent, an inhibitor
months. In the conditions of this study, the lotion
of the Wnt/ß-catenin pathway that causes the
containing 0.3 percent
hair cycle to enter latency
Hairgenyl stabilised
3. P16 by -71 percent, an inhibitor of the cell cycle
hair loss by limiting the
responsible for the premature senescence of
number of hairs lost by
dermal papilla fibroblasts.
-34.0 percent. This effect
In the components in epigenetics, 0.04 percent
was observed in 85 percent
Hairgenyl was tested on human hair follicle
of the volunteers.
dermal papilla cells treated with DHT. Results
Figure 3: Pichia minuta yeast, isolated from Rhododendron indicum flowers
A final self-evaluation
showed the active ingredient limits the
by volunteers confirmed
expression of two miRNAs, the source genes,
the efficacy of Hairgenyl. It
which are essential for hair growth. These
considerably reduced hair
are 3663-3p miRNA and let-7a-3p, by -50 and
loss in all the volunteers
-89 percent respectively.
who tested the product.
100 percent biotechnological Hairgenyl was developed using Silab’s extensive expertise in biotechnology. The active ingredient is rich in peptides obtained from the yeast Pichia minuta, which is isolated from Azalea flowers. This patented product is a preservative-free powder, resulting from a non-denaturing industrial process.
P C Review | JUNE 2017 |
35